Albany, NY -- (SBWIRE) -- 03/05/2018 -- Phenylketonuria is a genetic disorder, which means it is inherited from one’s parents. In this disease, the patient suffers from a metabolic defect, wherein the body is unable to break down phenylalanine amino acid that is made of protein. Phenylalanine starts accumulating in the blood stream and eventually, it damages the brain. This happens due to mutations in the PAH gene, which result in low levels of the enzyme called phenylalanine hydroxylase. Intellectual impairment, hyperactivity, and mental health disorder are neurological symptoms of phenylketonuria.
Skin rashes and order on the skin are physiological symptoms of the disease. If both parents are carriers of PKU, there exists a 25% possibility that their child would be conceived with the confusion; a 50% possibility that the kid would be a transporter; and a 25% possibility that it would neither create nor transport the illness. The fundamental approach to treat PKU is to eat a special diet that cuts off the food containing phenylalanine. Newborn children with PKU can be fed with breast milk. They for the most part likewise need to expend an uncommon recipe known as Lofenalac. At the point of the time when the child has grown enough to eat solid food, giving it a chance to eat foods high in protein needs to be avoided.
Request to View Brochure of Report -
Based on type, the Phenylketonuria Market has been segmented into classic PKU, mild PKU, and benign PKU. Moreover, classic PKU is most common type of phenylketonuria, which results in severe brain damage. Based on test, the phenylketonuria market has been divided into diagnostic test and screening test. The screening test segment is expanding at a rapid pace, as the screening test helps detect the disease at its earliest and most treatable stage, especially for the newborn baby. Based on treatment, the phenylketonuria market has been segmented into drug therapy, dietary therapy, gene therapy, and others.
Furthermore, the drug therapy segment has been sub-divided into oral therapy and parenteral therapy. The drug therapy segment is expanding by holding a large market share, as external drugs such as sapropterin dihydrochloride are required to combat the disease. The drug therapy works effectively fulfilling the requirements and maintaining the phenylalanine level in the blood. The market for phenylketonuria in developed economies is witnessing growth, owing to the large number of patients suffering from phenylketonuria, high awareness about the disease, and high diagnostic rate of the disease in these countries. However, issues related to newborn screening is a factor that restricts the phenylketonuria market.
Request to View ToC of Report -
Based on geography, the global phenylketonuria market has been segmented into North America, Europe, Asia Pacific, Latin America, and MEA. The North America phenylketonuria treatment market is expected to hold a high market share during the forecast period, due to the rising number of newborns suffering from phenylketonuria in the region. The rise in awareness among people and improved health care infrastructure in Europe boost the market in the region. The market in Asia Pacific is projected to expand at a significant rate during the forecast period, due to large pool of patients and increase in R&D activities for the development of drugs for phenylketonuria in the region. Moreover, growing economy and availability of newborn screening infrastructure and different screening programs augment the phenylketonuria market in Middle East & Africa.
Some of the key players operating in the global phenylketonuria market are American Gene Technologies International Inc., Dimension Therapeutics, Inc., BioMarin Pharmaceutical Inc., Synthetic Biologics, Inc., Codexis, Inc., SOM Innovation Biotech SL, Daiichi Sankyo Company, Limited, and Erytech Pharma SA.
Enquiry for discount on this report -